Print

Immunomedics, Inc. (IMMU) Release: Addition of Epratuzumab to Combination Chemotherapy May be Beneficial in Acute Lymphocytic Leukemia  
12/10/2012 9:12:12 AM

ATLANTA, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU),a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that adult patients with relapsed or refractory acute lymphocytic leukemia (ALL) reported a complete response (CR and CRi) rate of 50% after receiving one cycle of treatment with epratuzumab in combination with the chemotherapy agents, clofarabine and cytarabine.
//-->